Centrexion Therapeutics Corp:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Centrexion Therapeutics Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C3306)・商品コード:DATA904C3306
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:42
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Centrexion Therapeutics Corp (Centrexion Therapeutics), formerly Centrexion Corp is a developer of clinical pipelines of novel and non opioid chronic pain therapy products. The company offers products such as CNTX-4975, CNTX- 0290, CNTX-6970, CNTX-2022, CNTX-6016 and Intrathecalplatform. Its synthetic trans capsaicin ultra-pure injection develops a proprietary injectable therapy designed to provide fast acting, long lasting and targeted pain relief. Centrexion Therapeutics products are used to treat morton’s neuroma and knee osteoarthritis. The company’s research and clinical trial develops novel pain therapeutics for various conditions. Centrexion Therapeutics is headquartered in Boston, Massachusetts, the US.

Centrexion Therapeutics Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Centrexion Therapeutics Acquires Three New Analgesic Candidates from Boehringer Ingelheim 11
Venture Financing 13
Centrexion Therapeutics Raises USD67 Million in Series D Financing 13
Centrexion Therapeutics Raises USD5.3 Million in Venture Financing 15
Centrexion Therapeutics Raises USD16.6 Million in Venture Financing 16
Centrexion Therapeutics Raises USD11.1 Million in Financing Round 17
Centrexion Therapeutics Raises USD7 Million in Venture Financing 18
Centrexion Raises USD14.7 Million in Venture Financing 19
Centrexion Therapeutics Raises USD8.8 Million in Financing Round 20
Debt Offering 21
Centrexion Therapeutics Raises USD10.5 Million Private Placement of Notes 21
Centrexion Therapeutics Corp – Key Competitors 22
Centrexion Therapeutics Corp – Key Employees 23
Centrexion Therapeutics Corp – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Corporate Communications 25
Aug 15, 2018: Centrexion Therapeutics names Dan Mendelson as Board Director 25
Jul 30, 2018: Centrexion Therapeutics names Nick Harvey as chief financial officer 26
Jun 26, 2018: Centrexion Therapeutics Names Joseph R. Swedish As Board Director 27
Jun 26, 2017: Centrexion Therapeutics Names Shawn Tomasello to its Board of Directors 28
Product News 29
08/29/2017: Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek 2017 29
06/07/2017: Centrexion Therapeutics Announces Oral Presentation of Six Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at the Annual European Congress of Rheumatology 30
05/10/2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma and Knee Osteoarthritis at American Pain Society 2017 Annual Scientific Meeting 31
Product Approvals 32
Jan 16, 2018: Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain 32
Clinical Trials 33
Jan 02, 2018: Centrexion Therapeutics Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018 33
Oct 30, 2017: Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017 34
Sep 26, 2017: Centrexion Therapeutics to Present Phase 2b data of Osteoarthritis Drug Candidate CNTX-4975 at the 11th Annual Pain and Migraine Therapeutics Summit 35
Jul 20, 2017: Centrexion Therapeutics to Present Phase 2b Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma at the American Podiatric Medical Association 2017 Annual Scientific Meeting 36
Jun 13, 2017: Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain 37
May 25, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at European Federation of National Associations of Orthopaedics and Traumatologys 2017 Annual Congress 39
Mar 23, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 from the Treatment of Knee Osteoarthritis Pain at IX SIMPAR-ISURA 40
Mar 16, 2017: Centrexion Therapeutics to Present Late-Breaking Poster at the 33rd Annual American Academy of Pain Medicine Meeting 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Key Facts 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Centrexion Therapeutics Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Centrexion Therapeutics Acquires Three New Analgesic Candidates from Boehringer Ingelheim 11
Centrexion Therapeutics Raises USD67 Million in Series D Financing 13
Centrexion Therapeutics Raises USD5.3 Million in Venture Financing 15
Centrexion Therapeutics Raises USD16.6 Million in Venture Financing 16
Centrexion Therapeutics Raises USD11.1 Million in Financing Round 17
Centrexion Therapeutics Raises USD7 Million in Venture Financing 18
Centrexion Raises USD14.7 Million in Venture Financing 19
Centrexion Therapeutics Raises USD8.8 Million in Financing Round 20
Centrexion Therapeutics Raises USD10.5 Million Private Placement of Notes 21
Centrexion Therapeutics Corp, Key Competitors 22
Centrexion Therapeutics Corp, Key Employees 23

List of Figures
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Centrexion Therapeutics Corp:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C3306)販売に関する免責事項を必ずご確認ください。
★調査レポート[Centrexion Therapeutics Corp:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆